TradingKey

关于 ACADIA Pharmaceuticals Inc 公司

Acadia Pharmaceuticals Inc. 是一家生物制药公司。该公司专注于开发和商业化药物，以满足中枢神经系统 (CNS) 疾病和罕见疾病中未满足的医疗需求。该公司拥有一系列商业阶段产品、开发中产品机会和研究项目，旨在满足中枢神经系统疾病和罕见疾病中未满足的需求。其产品线包括 NUPLAZID（匹莫范色林）、DAYBUE（曲芬奈肽）、ACP-101、ACP-204 和反义寡核苷酸 (ASO) 项目。NUPLAZID 是一种选择性血清素反向激动剂/拮抗剂，优先针对 5-HT2A 受体。NUPLAZID 专为治疗帕金森病精神病而开发。曲芬奈肽是胰岛素样生长因子 1 (IGF-1) 氨基末端三肽的一种新型合成类似物，旨在通过减少神经炎症和支持突触功能来治疗雷特综合征的核心症状。

公司简介

公司代码ACAD

公司名称ACADIA Pharmaceuticals Inc

上市日期May 27, 2004

CEOMs. Catherine Owen Adams

员工数量653

证券类型Ordinary Share

年结日May 27

公司地址12830 El Camino Real

城市SAN DIEGO

上市交易所NASDAQ Global Select Consolidated

国家United States of America

邮编92130

电话18585582871

网址https://acadia.com/

公司代码ACAD

上市日期May 27, 2004

CEOMs. Catherine Owen Adams

公司高管

名称

名称/职务

职务

持股

持股变动

Mr. Julian C. Baker

Independent Director

102.88K

--

Mr. Daniel B. (Dan) Soland

Independent Director

44.04K

+27.09%

Dr. Adora Ndu, Pharm.D.

Independent Director

24.80K

+60.90%

Ms. Laura A. Brege

Independent Director

15.10K

-48.90%

Mr. James Michael (Jim) Daly

Independent Director

--

Dr. Stephen R. Biggar, M.D., Ph.D.

Independent Chairman of the Board

--

Dr. Elizabeth H. Z. Thompson, Ph.D.

Executive Vice President and Head of Research and Development

--

Mr. Mark C. Schneyer

Chief Financial Officer, Executive Vice President

--

Dr. Edmund P. Harrigan

Independent Director

--

Mr. Thomas Andrew (Tom) Garner

Executive Vice President, Chief Commercial Officer

--

名称

名称/职务

职务

持股

持股变动

Mr. Julian C. Baker

Independent Director

102.88K

--

Mr. Daniel B. (Dan) Soland

Independent Director

44.04K

+27.09%

Dr. Adora Ndu, Pharm.D.

Independent Director

24.80K

+60.90%

Ms. Laura A. Brege

Independent Director

15.10K

-48.90%

Mr. James Michael (Jim) Daly

Independent Director

--

Dr. Stephen R. Biggar, M.D., Ph.D.

Independent Chairman of the Board

--

收入明细

单位: USD更新时间: 7月6日周日

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023Q2

FY2023Q1

业务USD

名称

营收

占比

NUPLAZID

159.72M

65.37%

DAYBUE

84.60M

34.63%

暂无数据

业务

地区

业务USD

名称

营收

占比

NUPLAZID

159.72M

65.37%

DAYBUE

84.60M

34.63%

股东统计

更新时间: 5月17日周六

持股股东

股东类型

持股股东

占比

Baker Bros. Advisors LP

25.62%

BlackRock Institutional Trust Company, N.A.

11.22%

The Vanguard Group, Inc.

9.07%

RTW Investments L.P.

5.10%

State Street Global Advisors (US)

4.18%

Other

44.81%

持股股东

占比

Baker Bros. Advisors LP

25.62%

BlackRock Institutional Trust Company, N.A.

11.22%

The Vanguard Group, Inc.

9.07%

RTW Investments L.P.

5.10%

State Street Global Advisors (US)

4.18%

Other

44.81%

股东类型

持股股东

占比

Investment Advisor

36.94%

Hedge Fund

36.72%

Investment Advisor/Hedge Fund

23.21%

Research Firm

4.68%

Pension Fund

1.03%

Sovereign Wealth Fund

0.88%

Individual Investor

0.58%

Bank and Trust

0.34%

Private Equity

0.28%

机构持股

更新时间: 7月1日周二

报告期

机构数

持股数

持股占比

持股变动

2025Q2

668

175.40M

104.80%

-13.00M

2025Q1

688

177.74M

106.20%

-7.86M

2024Q4

643

167.35M

100.34%

-11.57M

2024Q3

599

161.17M

97.17%

-22.69M

2024Q2

603

166.04M

100.49%

-20.26M

2024Q1

612

167.37M

101.58%

-15.73M

2023Q4

589

164.89M

100.43%

-16.10M

2023Q3

560

161.37M

98.56%

-19.17M

2023Q2

557

164.35M

101.06%

-15.99M

2023Q1

589

162.49M

100.16%

-17.75M

股东持股明细

名称

持股数

占比

持股变动

变动比例

公告日期

Baker Bros. Advisors LP

42.88M

25.62%

--

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

18.77M

11.22%

+8.64M

+85.36%

Mar 31, 2025

The Vanguard Group, Inc.

15.18M

9.07%

+1.26M

+9.02%

Mar 31, 2025

RTW Investments L.P.

8.54M

5.1%

-165.38K

-1.90%

Mar 31, 2025

State Street Global Advisors (US)

6.99M

4.18%

+2.47M

+54.68%

Mar 31, 2025

Point72 Asset Management, L.P.

4.65M

2.78%

+2.42M

+108.35%

Mar 31, 2025

Morgan Stanley & Co. LLC

4.26M

2.54%

-1.74M

-29.03%

Mar 31, 2025

Geode Capital Management, L.L.C.

2.95M

1.77%

+77.40K

+2.69%

Mar 31, 2025

Fred Alger Management, LLC

2.77M

1.66%

+54.90K

+2.02%

Mar 31, 2025

Palo Alto Investors LP

2.66M

1.59%

-84.67K

-3.08%

Mar 31, 2025

持股ETF

更新时间: 8月2日周六

机构名称

占比

Alger Weatherbie Enduring Growth ETF

4.69%

First Trust NYSE Arca Biotechnology Index Fund

4.65%

iShares Neuroscience and Healthcare ETF

4.3%

Invesco Biotechnology & Genome ETF

2.58%

ALPS Medical Breakthroughs ETF

2.44%

Tema Neuroscience and Mental Health ETF

2.36%

Virtus LifeSci Biotech Products ETF

1.91%

Invesco S&P SmallCap Health Care ETF

1.91%

Pacer US Small Cap Cash Cows Growth Leaders ETF

1.82%

Invesco Dorsey Wright Healthcare Momentum ETF

1.58%

Alger Weatherbie Enduring Growth ETF

占比4.69%

First Trust NYSE Arca Biotechnology Index Fund

占比4.65%

iShares Neuroscience and Healthcare ETF

占比4.3%

Invesco Biotechnology & Genome ETF

占比2.58%

ALPS Medical Breakthroughs ETF

占比2.44%

Tema Neuroscience and Mental Health ETF

占比2.36%

Virtus LifeSci Biotech Products ETF

占比1.91%

Invesco S&P SmallCap Health Care ETF

占比1.91%

Pacer US Small Cap Cash Cows Growth Leaders ETF

占比1.82%

Invesco Dorsey Wright Healthcare Momentum ETF

占比1.58%

分红派息

近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股

公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

ACADIA Pharmaceuticals Inc

23.530USD

ACADIA Pharmaceuticals Inc

23.530

概览

公司

财务